Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a %26quot;standard chemotherapy regimen%26quot;: The CASA randomized trial

作者：Crivellari Diana^*; Gray Kathryn P; Dellapasqua Silvia; Puglisi Fabio; Ribi Karin; Price Karen N; Lang Istvan; Gianni Lorenzo; Spazzapan Simon; Pinotti Graziella; Luethi Jean Marc; Gelber Richard D; Regan Meredith M; Colleoni Marco; Castiglione Gertsch Monica; Maibach Rudolf; Rabaglio Manuela; Coates Alan S; Goldhirsch Aron

来源：Breast, 2013, 22(2): 130-137.

DOI：10.1016/j.breast.2013.01.015

• Adjuvant treatment
• Endocrine nonresponsive
• Chemotherapy
• Pegylated liposomal doxorubicin
• Elderly
• Breast cancer

There is no optimal treatment for breast cancers lacking estrogen (ER) and progesterone (PgR) receptors in elderly women with co-morbidities that prevent use of %26quot;standard chemotherapy regimens%26quot; such as AC or CMF. The CASA trial studied pegylated liposomal doxorubicin (PLD) and low dose, metronomic cyclophosphamide methotrexate (CM) for older (%26gt;65), vulnerable women with operable, ER and PgR-negative breast cancer. After two years the trial closed early, due to slow and inadequate accrual, with 77 patients (38:PLD, 36:CM, 3:nil). Sixty-eight percent completed PLD; 83% completed CM (both 16 weeks). Patients on PLD reported worse quality of life, cognitive and physical functioning than non-PLD regimens (primarily CM). At a median follow-up of 42 months, 81% of randomized patients remained free of any breast cancer recurrence. Based on our limited experience, PLD and CM may be reasonable options for further study for elderly vulnerable patients with endocrine nonresponsive breast cancer.

• 出版日期2013-4